You are here

Therapeutic Advances in Cardiovascular Disease

Therapeutic Advances in Cardiovascular Disease


eISSN: 17539455 | ISSN: 17539447 | Current volume: 19 | Current issue: 1 Frequency: Yearly

Launched in 2007, Therapeutic Advances in Cardiovascular Disease is a gold open access journal publishing clinically focused cardiovascular research that optimises treatment strategies across the care pathway, enables real-world implementation, and improves patient and service outcomes. All articles are made freely available online upon publication, supporting the rapid and global dissemination of evidence that informs patient care.

The journal publishes original research articles, systematic and narrative reviews, consensus statements and guidelines, study protocols, and case reports/series that address how cardiovascular disease is treated in practice, with particular emphasis on studies that clarify clinical decision-making, optimise therapeutic strategies, and improve outcomes across diverse patient populations. For more information about article types and topical priorities, please refer to the Aims and Scope page.

Our goal is to publish novel research, even if it represents an incremental advance. While our primary focus is on ensuring sound scientific practices, including adherence to ethical standards and the use of robust, transparent, and reproducible methodologies, we recognise the value of incremental contributions to the field. We care more about the quality and reliability of the contribution an article makes than we do the size of that contribution. Therapeutic Advances in Cardiovascular Disease evaluates manuscripts based on how the research was conducted and reported.

All submissions undergo rigorous peer review and are evaluated for clinical relevance, methodological quality, and therapeutic impact. Therapeutic Advances in Cardiovascular Disease is indexed in MEDLINE, PubMed Central, Clarivate Analytics' Emerging Sources Citation Index (ESCI), and Scopus, and is a member of the Committee on Publication Ethics (COPE).

Accessible formats and article enhancements

Therapeutic Advances in Cardiovascular Disease also offers alternative article formats including Plain Language Summaries of Publications (PLS-Ps; standalone, peer-reviewed summaries of previously published articles), and podcast and clinical image articles, as well as article enhancements such as video abstracts and infographics. These formats extend the journal's educational reach, helping clinicians, generalist healthcare professionals, patients, caregivers, and policymakers engage with evidence, and align with our commitment to inclusive, real-world communication. For queries about these formats, please contact Dr. Amy Goundry at amy.goundry@sagepub.co.uk prior to submission.

Diversity, Equity and Inclusion statement

Therapeutic Advances in Cardiovascular Disease promotes inclusive, open science that reflects the disciplinary, human, and geographic diversity of the research community.

Diversity as a core value embodies inclusiveness, mutual respect, and multiple perspectives.

We welcome editors, editorial board members, peer reviewers, and authors from all backgrounds, cultures, ethnicities, nationalities, races, religions, sexes, sexual orientations, gender identities, mental or physical (dis)abilities, ages, career stages, socioeconomic status, or any other individual status.

We are committed to continually improving our editorial and review processes whilst playing our part in eradicating bias and inequality in all forms.

Submission information

Submit your manuscript at http://mc.manuscriptcentral.com/tac.

Please see the Submission Guidelines for more information on preparing and submitting your article.

Open access information

The article processing charge (APC) for this journal is currently $3000 USD*.

*APC for original research articles, brief reports, systematic reviews and meta-analyses, narrative reviews, study protocols, and case reports/series.

Pre-submission queries

Pre-submission enquiries are welcome. Authors proposing accessible formats (i.e., PLS-Ps and podcast or clinical image articles) should contact the Managing Editor before submitting. We also invite general questions about scope alignment, clinical positioning, and submissions to current Special Collections.

Please direct pre-submission queries to Dr. Amy Goundry at amy.goundry@sagepub.co.uk.

Subject line: TAK Pre-Submission Query — [Article Type] — [Special Collection, if any]

For questions about a submitted paper or to request an extension for a review or revision, please contact the journal's editorial office at cardio@sagepub.co.uk.

Therapeutic Advances in Cardiovascular Disease is a peer-reviewed, gold open access journal dedicated to publishing clinically focused cardiovascular research that optimises treatment strategies across the care pathway, enables real-world implementation, and improves patient and service outcomes.

The journal covers the full spectrum of cardiovascular care, from prevention and diagnosis to treatment optimisation and long-term management, helping clinicians choose, tailor, and refine therapies in real-world practice and across diverse patient populations. This includes decision-relevant health systems and services research on models of care, implementation strategies, service delivery, equity of access, and the translation of evidence into practice. Such research should demonstrably inform treatment choices or care pathways and report patient- or service-level outcomes.

The journal considers:

  • Original research (observational, interventional, comparative-effectiveness, implementation, and service-delivery studies) that evaluate therapies, care pathways, or models of care and report clinical, utilisation, equity, or implementation outcomes.
  • Systematic and narrative reviews that clarify treatment choices or care pathways.
  • Consensus statements/guidelines that translate evidence into actionable treatment algorithms.
  • Study protocols for comparative-effectiveness or implementation studies with direct therapeutic relevance.
  • Case reports and series with clear management implications (e.g., change in treatment selection, timing, dose, sequencing, or monitoring), and follow-up outcomes where feasible.

Topics of particular interest include:

  • Comparative effectiveness and treatment strategies
  • Therapeutic optimisation (dose, duration, combinations, sequencing)
  • Precision/personalised approaches with clinical validation
  • Long-term outcomes and equity in therapy delivery
  • Implementation science and service-model evaluations (e.g., care pathways, digital decision support, pharmacist-led titration) linked to clinical or utilisation outcomes
  • Emerging technologies (e.g., imaging, AI, devices) with demonstrable impact on clinical decisions (selection, timing, monitoring) and, where possible, patient outcomes

Therapeutic Advances in Cardiovascular Disease actively encourages well-designed studies reporting null or neutral results when they clearly inform practice.

Preclinical or purely mechanistic/biomarker-discovery work without clinical validation is not considered (e.g., animal or in vitro studies; omics/microRNA discovery without patient-level decision impact). Economic or policy analyses without accompanying clinical, utilisation, or implementation outcomes; descriptive audits without decision relevance; and purely epidemiological reports are out of scope.

Reporting and transparency standards

Where applicable, submissions should adhere to established reporting guidelines and best practice:

  • CONSORT for randomised trials, STROBE for observational studies, PRISMA for systematic reviews, SPIRIT for protocols, and CARE for care reports/series.
  • Trial registration in a WHO-approved registry for interventional studies at or before first patient enrolment.
  • Clear statements on ethical considerations and consent to participate.
  • Data availability and declaration of conflicting interest statements consistent with ICMJE recommendations.

Audience and reach

Therapeutic Advances in Cardiovascular Disease serves an international readership of clinicians, clinical researchers, healthcare professionals, and cardiovascular teams, offering rapid, global dissemination via gold open access.

Accessible formats and article enhancements

To maximise accessibility and impact, Therapeutic Advances in Cardiovascular Disease also supports a range of alternative article formats including Plain Language Summaries of Publications (PLS-Ps; standalone, peer-reviewed summaries of previously published articles) and podcast and clinical image articles. These formats extend the journal's educational reach, helping clinicians, generalist healthcare professionals, patients, caregivers, and policymakers engage with evidence, and align with our commitment to inclusive, real-world communication. For queries about these formats, please contact Dr. Amy Goundry at amy.goundry@sagepub.co.uk prior to submission.

Managing Editor
Amy Goundry, PhD SAGE Publications Ltd, UK
Assistant Managing Editor
Atharva Gajanan Gajalkar SAGE Publishing, India
Associate Editors
Arduino Mangoni MD, PhD Flinders Medical Centre and Flinders University, Bedford Park, Australia
Phyo Myint MBBS, MD, FRCP (Edin) Institute of Applied Health Sciences, School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, Aberdeen, United Kingdom
Biostatistical Editors
Robert J. Chen, MD, MPH Stanford University School of Medicine, Cardiothoracic Surgery, USA
Dario Gregori, PhD, FTOS, FACN University of Padua, Italy
Chenghui Li, PhD University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
Diversity, Equity and Inclusion Editor
F. Aaysha Cader MBBS, MD, MRCP (UK) Ibrahim Cardiac Hospital & Research Institute, Dhaka, Bangladesh
Editorial Board
Luis Alcocer MD Hospital General of Mexico, Mexico City (Magdalena Contreras), Mexico
Dr. Ahmed Alsinbili Milton Keynes University Hospital Oxford, UK
Matteo Beltrami Careggi University Hospital, Florence, Italy
Josephine P. Briggs MD National Center for Complementary and Integrative Health (NCCIH), Maryland, USA
Victoria M. Cachofeiro MD Universidad Complutense, Madrid, Spain
Jose Cangiano MD Sociedad de Nefrología e Hipertensión de Puerto Rico, Puerto Rico
Larisa Cavallari University of Florida, Gainesville, FL, USA
Angel Chamorro MD University of Barcelona, Spain
Thomas M. Coffman MD Duke University Medical Center, Durham, North Carolina, USA
Zainab A. Dakhil, FIMBS Cardiol, FIBMS Med, FABHS Med, DM Chest diseases, DM Med, MBChB, MACC, MESC, Ibn Al Bitar Cardiac Centre, Al-Kindy College of Medicine, Iraq
Kevin P Davy Ph.D. Virginia Polytechnic Institute and State University, Blacksburg, USA
Javier Diez MD University of Navarra, Pamplona, Spain
Bonita Falkner MD Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA
Gregory Fink MD Michigan State University, East Lansing, Michigan, USA
John M Flack MD Southern Illinois University, Illinois, USA
John Floras MD University of Toronto, Toronto, Ontario, Canada
Toshiro Fujita MD The University of Tokyo, Tokyo, Japan
Cristina Gavina MD, PhD Hospital Pedro Hispano, Portugal
Randolph L Geary MD Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
Vadim Genkel South-Ural State Medical University, Chelyabinsk, Russia
Seyed Mehrdad Hamrahian, MD Thomas Jefferson University in Philadelphia, PA, USA
Parta Hatamizadeh University of Florida Health, Florida, USA
Pedro Jose MD Georgetown University Medical Center, Washington D.C., USA
Luis Juncos MD National University of Cordoba, Cordoba, Argentina
Efstratios Koutroumpakis, MD MD Anderson Cancer Centre, University of Texas, USA
Jose E. Krieger MD University of Sco Paulo Medical School, Sco Paulo, Brazil
Pavel J Levy MD Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
Anastasios (Tassos) Lymperopoulos NSU College of Pharmacy, Nova Southeastern University, United States
Giuseppe Mancia MD, PhD University of Milan - Bicocca, Monza, Italy
Jawahar L Mehta MD, PhD University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
Nicola Mumoli, MD Ospedale Civile di Busto Arsizio, ASST Valle Olona, Busto Arsizio, Italy
Mohan Raizada MD, PhD University of Florida, Florida, USA
Josep Redon MD, PhD Hospital Clinico Universitario, Universidad de Valencia, Valencia, Spain
Kathryn Sandberg PhD Georgetown University, Washington D.C., USA
Rameen Shakur MD, PhD(Cantab), FRSA, FIBMS, FRSPH University of Brighton, Brighton, United Kingdom
Rhian M. Touyz MBBCh, MSc, PhD University of Glasgow, Glasgow, Scotland, UK
Jasmina Varagic MD, PhD National Heart, Lung, and Blood Institute (NHLBI), Bethesda, USA
George Vauquelin MD, PHD Vrije Universiteit Brussels, Brussels, Belgium
Massimo Volpe MD Ospedale Sant'Andrea, Univerisity "La Sapienza" Rome, Italy
R Clinton Webb PhD, MS Medical College of Georgia, Augusta, Georgia, USA
Matthew R. Weir MD University of Maryland School of Medicine, Baltimore, Maryland, USA
Bryan Williams MD University of Leicester, Leicester, UK
Yoram Yagil PhD, MD Ben-Gurion University, Ashkelon, Israel
Irving Zucker PhD, MD University of Nebraska Medical Center, Omaha, Nebraska, USA
Editorial Review Board
Avinash Anantharaj, MBBS, MD, DM, PDF Jawaharlal Institute of Post graduate Medical Education and Research (JIPMER) Puducherry, India
Zhipeng Bao, MSc The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
Moustafa Dawood, MBBCh, MSc, PhD, FSCAI Alexandria University, Alexandria, Egypt
Doaa El Amrousy, MD Tanta University, Egypt
Tuncay Güzel, MD Health Science University, Gazi Yasargil Training and Research Hospital, Diyarbakir, Turkey
Raymond Haddad, MD, MHSc, PhDc, FPICS Marie Lannelongue Hospital, Université Paris-Saclay, Le Plessis-Robinson, France
Jibran Ikram, MD Heart Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA
Rabia Islam, MBBS Harvard TH-chan school of public health, Boston, USA
Yasuhiko Kawaguchi, MD London Health Sciences Centre, Western University, London, ON, Canada
Kiyonori Kobayashi, PT, MSc Nagoya University Hospital, Nagoya, Japan
Krishna Prasad Kurpad, MBBS University of Texas Medical Branch, Galveston, TX, USA
Wael Saade, MD La Sapienza University of Rome, Rome, Italy
Sandeep Ajoy Saha, MD, MS, FACC, FHRS Oregon Heart Center, Salem, Oregon, USA
Alon Shechter, MD, MHA Rabin Medical Center, Israel
Zhanhao Su, MD, PhD Provincial People's Hospital, Guangzhou, China
Irfan Ullah, MBBS, MPH University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA
  • Directory of Open Access Journals (DOAJ)
  • ProQuest
  • PubMed: MEDLINE
  • PubMed: PubMed Central (PMC)
  • Scopus
  • Web of Science: Emerging Sources Citation Index (ESCI)
  • EC Rep

    International Associates Auditing & Certification Limited
    The Black Church, St Mary's Place,
    Dublin 7, D07 P4AX Ireland
    Sage's GPSR statement